We’ve long said that it can pay to specialize within the orthopedic market. This is especially true in the spine segment, where more focused companies regularly grow faster than their diversified counterparts. However, it holds true in other areas of the market as well.
Our chart of the month shows total revenue from 2018 through 2022 projected close for five mid- to small-tier companies: ATEC, Paragon 28, Vericel, Treace Medical Concepts and OrthoPediatrics. Over that span, these companies far outpaced the market growth rate in their respective segments. While all of these companies have executed well, we see ATEC and Treace Medical Concepts as two of the premier growth stories in orthopedics.
ATEC has long pointed to its holistic view of procedural spine surgery as the driving factor in its success. Since 2020, ATEC’s growth rate has skyrocketed due to competitive wins and filling geographic white spaces. The company boasts a 5-year CAGR of nearly 29%. Armed with differentiated enabling technology from its EOS acquisition, ATEC has a clear path to $550+ million in revenue by 2025.
As the largest orthopedic companies invest more heavily in foot and ankle, Treace’s sole focus on bunion surgery has led to a 5-year CAGR of almost 38%. The company has penetrated only 20% of its target market, leaving ample runway for future growth.
We’ve long said that it can pay to specialize within the orthopedic market. This is especially true in the spine segment, where more focused companies regularly grow faster than their diversified counterparts. However, it holds true in other areas of the market as well.
Our chart of the month shows total revenue from 2018 through 2022...
We’ve long said that it can pay to specialize within the orthopedic market. This is especially true in the spine segment, where more focused companies regularly grow faster than their diversified counterparts. However, it holds true in other areas of the market as well.
Our chart of the month shows total revenue from 2018 through 2022 projected close for five mid- to small-tier companies: ATEC, Paragon 28, Vericel, Treace Medical Concepts and OrthoPediatrics. Over that span, these companies far outpaced the market growth rate in their respective segments. While all of these companies have executed well, we see ATEC and Treace Medical Concepts as two of the premier growth stories in orthopedics.
ATEC has long pointed to its holistic view of procedural spine surgery as the driving factor in its success. Since 2020, ATEC’s growth rate has skyrocketed due to competitive wins and filling geographic white spaces. The company boasts a 5-year CAGR of nearly 29%. Armed with differentiated enabling technology from its EOS acquisition, ATEC has a clear path to $550+ million in revenue by 2025.
As the largest orthopedic companies invest more heavily in foot and ankle, Treace’s sole focus on bunion surgery has led to a 5-year CAGR of almost 38%. The company has penetrated only 20% of its target market, leaving ample runway for future growth.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.
Copy to clipboard 
